Jiangsu Jibeier Pharmaceutical Co., Ltd.

The company was founded in 2001 and is a high-tech pharmaceutical enterprise specializing in drug research and development and manufacturing, focusing on innovative drugs. On May 18, 2020, the company officially landed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. After years of development, the company has formed a diversified product line focusing on high-tech products such as the brightening drug Liquorcan tablets and the compound anti-hypertensive drug Nicunolol tablets, and is committed to the research and development of innovative drugs to treat diseases such as depression, tumors, and stomach problems to meet the needs of the market and clinical medication. The company is a high-tech enterprise specializing in drug research and development. The product functions cover various treatment fields such as improving white blood cells, fighting high blood pressure, enhancing immunity, treating joint diseases, eye infections, treating bronchitis, and protecting liver function, and is committed to the research and development of innovative drugs to treat diseases such as depression, tumors, and stomach problems. The company's products are mainly ricojun tablets, niqunolol tablets, aceclofenac enteric tablets, xicinone tablets, yupingfeng capsules, yiganling capsules, gatifloxacin eye drops, and lomefloxacin hydrochloride eye drops. Company honors: Famous trademarks in Jiangsu Province, contract-abiding and credit-worthy enterprises, postdoctoral research workstations, etc.